Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The company is developing two primary product candidates: ATRN-119 (an oral ATR inhibitor) and APR-1051 (an oral WEE1 inhibitor). This summary covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Grant Revenue | $162,463 | $380,569 |
| Total Operating Expenses | $4,248,045 | $3,530,239 |
| Net Loss | $(3,932,659) | $(2,810,091) |
| Net Loss Per Share (Basic & Diluted) | $(0.66) | $(0.67) |
| Cash and Cash Equivalents (End of Period) | $19,275,721 | $32,369,973 |
| Accumulated Deficit | $(324,974,531) | $(310,893,252) |
| Net Cash Used in Operating Activities | $(3,631,163) | $(3,935,891) |
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue decreased by approximately $218,000 (57%) compared to Q1 2024, primarily due to lower grant funding from the National Cancer Institute.
- Increased Operating Expenses: Total operating expenses rose by $717,806 (20%). Research and Development (R&D) expenses increased by $882,693, driven by the initiation of the Phase 1 dose-escalation study for APR-1051 and continued enrollment in the ABOYA-119 trial for ATRN-119. General and Administrative (G&A) expenses decreased by $164,887 due to lower professional fees.
- Widened Net Loss: Net loss increased by $1.12 million to $3.93 million, reflecting higher R&D spend and lower grant revenue.
- Cash Burn: Cash and cash equivalents decreased by approximately $3.6 million during the quarter. The company utilized $55,849 in net financing proceeds from an At-the-Market (ATM) offering.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. The current cash balance of approximately $19.3 million is not sufficient to fund operations for at least twelve months from the filing date. The company is actively seeking additional funding.
- Clinical Milestones:
- APR-1051: First patient enrolled in the ACESOT-1051 Phase 1 study in Q2 2024. Open-label safety/efficacy data is anticipated in the second half of 2025, with dose-escalation completion expected in the first half of 2026.
- ATRN-119: Enrollment continues in the ABOYA-119 Phase 1/2a trial. Open-label safety/efficacy data is anticipated in the second half of 2025, with Recommended Phase 2 Dose (RP2D) determination expected in the first half of 2026.
- Financing Activities: The company maintains an ATM agreement allowing for the sale of up to $3.0 million of common stock. In Q1 2025, 22,406 shares were sold for net proceeds of approximately $0.1 million.
- Risk Factors: Key risks include the failure of clinical trials, inability to secure additional capital, dependence on third-party manufacturers, and potential intellectual property challenges. The company has no commercial product revenue and expects to incur losses for the foreseeable future.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing additional financing given the explicit "substantial doubt" regarding the going concern status.
- Clinical Enrollment Rates: Monitor patient enrollment progress for the ACESOT-1051 and ABOYA-119 trials to ensure they meet the projected 2025/2026 data readout timelines.
- ATM Utilization: Track the remaining capacity under the $3.0 million ATM agreement and the frequency of share sales, which may indicate dilution pressure.
- Grant Funding Stability: Assess the sustainability of grant revenue, which declined significantly in Q1 2025.
- Capital Expenditure Plans: Review management's plans for cost reduction or scaling back development activities if additional funding is not secured.